Related Experiment Video
Updated: Mar 13, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Care beyond microbiological cure: A case control study comparing quality of life between MDRTB and drug-sensitive TB
Subhajoy Maitra1, Sayeli Mitra1, Sagnik Chakraborty2
1Department of Community Medicine, Jagannath Gupta Institute of Medical Sciences and Hospital, Kolkata, West Bengal, India.
Background:
The emergence of drug-resistant tuberculosis has become a significant public health problem and an obstacle to end tuberculosis. Despite the considerable attention given to traditional microbiological and clinical indicators in National TB programs, the effect of tuberculosis on the quality of life of patients has largely been neglected. This study was planned to compare the quality of life of MDR pulmonary tuberculosis with the drug-sensitive pulmonary tuberculosis and to find the association of different domains of quality of life with selected socio-demographic variables.
Methods:
This is a facility-based observational analytical study done at a District Tuberculosis Centre, Kolkata, with MDR adult pulmonary tuberculosis patients as cases and drug-sensitive adult pulmonary tuberculosis patients as controls selected in a 1:2 ratio (114 cases and 228 controls). WHOQOL BREF was used to estimate quality of life.
Results:
Wilcoxon signed rank test revealed a significant statistical difference in the mean value of quality-of-life transformed scores across each domain of WHO QOL BREF between cases and the control group (P < 0.001). QOL scores were compared by domains according to selected socio-demographic parameters, where sex, age, marital status, and educational status showed a significant statistical difference. Presence of comorbidity, being underweight, and history of tuberculosis have statistically significantly lower transformed score (P < 0.001) across all domains.
Conclusion:
The score of the MDR TB group was found to be lower than that of drug-sensitive TB group. A special package including the appointment of a counsellor at the point of treatment may be beneficial.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

